Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Search by expertise, name or affiliation
Antihypertensive therapy and cancer risk
Dirk Felmeden,
Gregory Lip
Birmingham Medical School
Cardiovascular Sciences
Research output
:
Contribution to journal
›
Review article
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Antihypertensive therapy and cancer risk'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Antihypertensive Therapy
100%
Cancer Risk
100%
Antihypertensive Drugs
60%
Neutral Effects
40%
Patients with Hypertension
20%
Clinical Practice Guidelines
20%
Cancer Mortality
20%
Hypertension
20%
Protective Effect
20%
Prospective Clinical Trial
20%
Oncogenesis
20%
Death Rate
20%
Hypertension Management
20%
Cancer Development
20%
Beta-blockers
20%
Current Treatment
20%
Data Linking
20%
Antihypertensive Drug Therapy
20%
Calcium Channel Antagonist
20%
Development Rate
20%
Diuretics
20%
Alpha-blockers
20%
ACE Inhibitors
20%
Cancer Drugs
20%
Cancer Inpatients
20%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Antihypertensive Therapy
100%
Antihypertensive Drug
60%
Clinical Trial
20%
Beta Adrenergic Receptor Blocking Agent
20%
Calcium Channel
20%
Mortality Rate
20%
Carcinogenesis
20%
Retrospective Study
20%
Antihypertensive Agent
20%
Dipeptidyl Carboxypeptidase Inhibitor
20%
Pharmacotherapy
20%
Diuretic Agent
20%
Alpha Adrenergic Receptor Blocking Agent
20%